Related Experiment Video
Updated: Feb 19, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Win statistics (win ratio, win odds, and net benefit): Noncollapsibility and standardization for randomized clinical
Gaohong Dong1, Margaret Gamalo-Siebers2, Ying Cui3
1iStats Inc., Long Island City, New York, USA.
Win statistics like the win ratio are generally noncollapsible across clinical trial data types. Stratified win statistics offer a standardization approach for complex outcome analyses, addressing concerns highlighted by the FDA.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Health Outcomes Research
Background:
- Win statistics, including the win ratio and win odds, are prevalent in clinical trial design and analysis across various disease areas.
- These statistics are crucial for evaluating treatment efficacy, particularly in cardiovascular diseases, oncology, and diabetes.
- Despite extensive research on statistical inference, the noncollapsibility of win statistics remains under-investigated, a critical issue noted in recent FDA guidance.
Purpose of the Study:
- To investigate the noncollapsibility of win statistics (win ratio, win odds, net benefit) in clinical trial data.
- To evaluate the collapsibility of these statistics across binary, continuous, and time-to-event data types.
- To propose solutions for analyzing prioritized multiple outcomes in the presence of noncollapsibility.
Main Methods:
- Analysis of win statistics' collapsibility using simulated and real-world clinical trial data.
- Examination of win ratio, win odds, and net benefit across binary, continuous, and time-to-event data structures.
- Application of statistical inference methods to assess noncollapsibility properties.
Main Results:
- The win ratio was found to be noncollapsible for all three data types (binary, continuous, time-to-event).
- Win odds and net benefit demonstrated collapsibility for binary data but were noncollapsible for continuous and time-to-event data.
- Overall, win statistics exhibit general noncollapsibility, necessitating careful interpretation and analysis.
Conclusions:
- Win statistics are generally noncollapsible, impacting their interpretation in clinical trial analysis.
- Stratified win statistics are proposed as a robust standardization method for analyzing prioritized multiple outcomes.
- This approach is particularly valuable in scenarios where noncollapsibility is a significant concern, aligning with FDA recommendations.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Statistical Software for Data Analysis and Clinical Trials
Testing a Claim about Population Proportion
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...